Fast Five Quiz: Weight Loss

Romesh Khardori, MD, PhD; Evelyn S. Marienberg, MD

Disclosures

November 08, 2022

Patients taking anti-obesity medications such as orlistat, phentermine/topiramate, naltrexone-bupropion, liraglutide, and semaglutide have been shown to lose 5%-12% more weight than those following a lifestyle plan alone.

Anti-obesity medications are approved for patients with a BMI ≥ 30 or a BMI ≥ 27 with a comorbidity. Other considerations include patients who are actively engaged in self-care, conscientious of their diet but struggling to make dietary changes, unable to lose or maintain a lower body weight, and who have a desire for improved health.

Most anti-obesity medications are intended for long-term use, as discontinuation may result in re-emergence of increased appetite and weight regain. An exception to this is phentermine, which is approved for short-term use only.

Anti-obesity medications should be used in conjunction with lifestyle modifications.

Learn more about anti-obesity medications.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....